Biomarin Pharmaceutical Inc (BMRN)

Pretax margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 541,763 391,451 298,679 237,353 188,563 151,678 108,105 72,146 149,576 100,560 56,304 35,609 -75,350 -55,636 -70,692 -127,121 -48,997 -11,918 59,120 59,498
Revenue (ttm) US$ in thousands 2,830,220 2,731,722 2,563,532 2,443,023 2,373,030 2,261,604 2,184,719 2,123,138 2,059,481 1,999,471 1,903,678 1,871,615 1,827,451 1,829,463 1,891,778 1,815,339 1,822,817 1,822,364 1,813,337 1,772,797
Pretax margin 19.14% 14.33% 11.65% 9.72% 7.95% 6.71% 4.95% 3.40% 7.26% 5.03% 2.96% 1.90% -4.12% -3.04% -3.74% -7.00% -2.69% -0.65% 3.26% 3.36%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $541,763K ÷ $2,830,220K
= 19.14%

Biomarin Pharmaceutical Inc's pretax margin has shown variability over the past few years. The company experienced negative pretax margins in the latter half of 2020 and into early 2021, indicating challenges in generating taxable profits relative to total revenue during that period. However, the pretax margin began to improve in the later part of 2021 and continued to increase steadily through 2022 and 2023.

From March 31, 2024, the pretax margin surged significantly to 9.72% and continued to trend upwards, reaching 19.14% by December 31, 2024. This remarkable improvement suggests that the company effectively managed its expenses and increased its operational efficiency, leading to higher profitability before taxes.

Overall, the positive trend in Biomarin Pharmaceutical Inc's pretax margin from 2022 to 2024 indicates improving financial health and sustainability in the company's operations. However, it is essential to continue monitoring this metric to ensure long-term profitability and financial stability.